Dapagliflozin
FDA OKs dapagliflozin for heart failure regardless of diabetes status, plus more top stories in cardiology
FDA approves dapagliflozin for HFrEF regardless of diabetes status
FDA approves dapagliflozin for HFrEF regardless of diabetes status
Top stories in endocrinology: Trial tests dapagliflozin as COVID-19 treatment, recommended diabetes agents in presence of coronavirus
Clinical trial investigates dapagliflozin for COVID-19 treatment

Recruitment for a global phase 3 trial is now underway to assess the potential of the SGLT2 inhibitor dapagliflozin as a treatment to reduce COVID-19 progression, complications and death among adults with cardiovascular, metabolic or renal risk factors, according to a press release from AstraZeneca and St. Luke’s Mid America Heart Institute.
DAPA-CKD trial stopped early after ‘overwhelming benefit’ observed with dapagliflozin

The phase 3 DAPA-CKD trial assessing the benefit of the SGLT2 inhibitor dapagliflozin in adults with chronic kidney disease will be stopped early after investigators reported an “overwhelming benefit” for reduction in worsening renal function or renal death compared with placebo, according to a press release from AstraZeneca.